ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2309건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 27 | Active, not recruiting | Vaccination Against COVID-19 in Cancer | Cancer | Biological: mRNA-1273 SARS-CoV-2 vaccine from Moderna | Not Applicable | University Medical Center Groningen | OTHER | 791 | All | 18 Years | NKI-AvL, Amsterdam, Netherlands UMCG, Groningen, Netherlands Erasmus MC, Rotterdam, Netherlands |
| 26 | Completed | Vaccination for Recovered Inpatients With COVID-19 (VATICO) | Covid19 | Biological: Moderna mRNA-1273 COVID-19 vaccine Biological: Pfizer BNT162b2 COVID-19 vaccine |
Phase 4 | National Institute of Allergy and Infectious Diseases (NIAID), University of Minnesota, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Heart, Lung, and Blood Institute (NHLBI), US Department of Veterans Affairs, Prevention and Early Treatment of Acute Lung Injury, Cardiothoracic Surgical Trials Network, Medical Research Council | NIH | 66 | All | 18 Years | Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd, Los Angeles, California, United States San Francisco VAMC (Site 074-002), 4150 Clement Street, San Francisco, California, United States Stanford University Hospitals & Clinics (Site 203-003), Stanford University, School of Medicine, 300 Pasteur Dr., Grant Bldg, Room S011, Stanford, California, United States Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Site 066-002), 1124 W. Carson St., CDCRC, Torrance, California, United States Public Health Institute at Denver Health (Site 017-004), 660 Bannock Street, Denver, Colorado, United States Washington DC VA Medical Center (Site 009-004), 50 Irving Street, NW., Washington, District of Columbia, United States Hillsborough County Health Department, University of South Florida (Site 032-001), 1105 E. Kennedy Blvd., Tampa, Florida, United States Minneapolis VA Medical Center (Site 105-001), 1 Veterans Drive, Minneapolis, Minnesota, United States Duke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States Wake Forest Baptist Health (Site 210-001), Medical Center Boulevard, Winston-Salem, North Carolina, United States Rhode Island Hospital (Site 080-036), 593 Eddy St., Providence, Rhode Island, United States The Miriam Hospital (Site 080-039), 164 Summit Ave., Providence, Rhode Island, United States CHRISTUS Spohn Shoreline Hospital (Site 080-001), 600 Elizabeth Street, Corpus Christi, Texas, United States UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor, Dallas, Texas, United States Parkland Health and Hospital Systems (Site 084-002), James Aston Ambulatory Care Center - Clinical Research Unit, 5303 Harry Hines Blvd., Ste U-9.300, Dallas, Texas, United States Salem VA Medical Center (Site 074-014), 1970 Roanoke Blvd., Salem, Virginia, United States Institute of Human Virology-Nigeria (Site 612-601), International Research Center of Excellence, Cadastral Zone COO Plot 62, after BAZE University, off CITEC Road, Abuja, Nigeria Tan Tock Seng Hospital (Site 612-201), National Center for Infectious Diseases (NCID), 11 Jalan Tan Tock Seng, Singapore, Singapore Hospital Universitari Vall d'Hebron (Site 626-033), Passeig Vall Hebron, 119-129, Barcelona, Spain Hospital Clinic de Barcelona (Site 626-004), Carrer de Villaroel 170, Barcelona, Spain Hospital Universitari Germans Trias i Pujol (Site 626-003) Carretera de Canyet, s/n, Barcelona, Spain Hospital Universitari Arnau de Vilanova (Site 026-035), Institut de Recerca Biomedica de Lleida, Av. Rovira Roure, 80, Lleida, Spain Hospital General Universitario Gregorio Maranon (Site 626-001), Servicio de Inmunologia Clinica, Departamento de Medicina Interna, Dr. Esquerdo, 46, Madrid, Spain University Hospital Zurich (Site 621-201), Raemistrasse 100, Zurich, Switzerland MRC/UVRI & LSHTM Uganda Research Unit (Site 634-601), Plot 51-59 Nakiwogo Road, P.O. Box 49, Entebbe, Uganda Gulu Regional Referral Hospital (Site 634-603), P.O. Box 160, Gulu, Uganda St. Francis Hospital, Nsambya (Site 634-607), Nsambya Road Nsambya Hill, P.O. Box 7146, Kampala, Uganda Makerere University Lung Institute (634-604), Mulago National Referral Hospital, Kampala, Uganda Lira Regional Referral Hospital (Site 634-605), Plot 9/19, 21-41 Ngetta Road Police Road, Lira, Uganda Masaka Regional Referral Hospital (Site 634-606), MRC/UVRI and LSHTM Uganda Research Unit, Plot 6 Circle Road, PO Box 556, Masaka, Uganda |
| 25 | Unknown status | Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge | Covid19 | Biological: IN01 vaccine | Phase 1 | Instituto Oncologico Dr Rosell, IN3BIO, PANGAEA | OTHER | 40 | All | 18 Years | Hospital El Pilar, Barcelona, Spain |
| 24 | Completed | Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) | Coronavirus Infection | Drug: vadadustat Drug: placebo |
Phase 2 | The University of Texas Health Science Center, Houston, Akebia Therapeutics Inc., United States Department of Defense | OTHER | 449 | All | 18 Years | The University of Texas Health Science Center at Houston, Houston, Texas, United States |
| 23 | Completed | Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough | Post COVID-19 | Drug: Montelukast Sodium Tablets | Not Applicable | Assiut University | OTHER | 64 | All | 18 Years ~ 80 Years | Aliae Mohamed-Hussein, Assiut, Egypt |
| 22 | Completed | VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation | COVID-19 | Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) | Phase 2 | Aerogen Pharma Limited, Ohio State University | INDUSTRY | 11 | All | 18 Years | Ohio State University, Columbus, Ohio, United States |
| 21 | Terminated | Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19 | Moderate COVID-19-infection | Drug: human SARS-CoV 2 specific T lymphocytes | Phase 1 | Universitatsklinikum Koln, ZKS Koln, Hannover Medical School, Miltenyi Biomedicine GmbH | OTHER | 1 | All | 18 Years ~ 99 Years | Department I for Internal Medicine University Hospital of Cologne, Cologne, NRW, Germany |
